RNA-positive 6 moths after completion of IFN therapy; c) "HCV RNA-positive partial response", those judged to have a partial response based on their serum ALT levels who remained HCV RNA-positive; d) "no change", those judged "no change" based on their serum ALT levels who remained HCV RNA-positive. HCV RNA was measured by RT-PCR with a 5' noncoding region primer. Statistical analysis Fisher's exact test, Wilcoxon's rank sum test, Spearman's rank correlation, and Student's t-test were used for statistical analyses. Differences were considered significant when P <0.05.
Results
A total of 176 patients were registered for the study, but 54 were excluded for the following reasons: 15 because blood transfusion could not be documented or had been received within 12 months and 39 because they did not complete the course of IFN due to adverse effects or being lost to follow-up. Thus, 122 patients (21 low-dose and 101 high-dose) were included in the study. Table 1 shows the characteristics of the 122 patients. Although there were more patients in the high-dose group than in the low-dose group, there were no significant differences between the groups in regard to sex, mean age, interval between from blood transfusion and the start of IFN therapy, or serum ALT or albumin levels. IFN efficacy based on serum ALT response (Table 2) Based on serum ALT levels, 43/122 (35.2%) had complete responses and 24/122 (19.7%) had partial responses. There were no significant differences between complete or partial response in the low-and high-dose groups. IFN efficacy based on HCV RNA (Table 3) In 68 patients, the HCV RNA level was assayed immediately before starting IFN administration, at the completion of IFN administration, and 6 months after completing IFN administration. As shown in Table 3 , 19/68 (27.9%) patients had a HCV-negative complete response, and 10/68 (14.7%) had a HCV-positive complete response. There were no significant differences between the low-and Table 1 Patients' clinical characteristics and laboratory findings Table 2 Evaluation of ALT response in the interferon-treated chronic hepatic C patients with a history of blood transfusion Table 3 Evaluation of HCV RNA and ALT response in the interferontreated chronic hepatitis C patients with a history of blood transfusion 
